Price/Book of Coherus BioSciences, Inc.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|ADVM Adverum Biotechnologies, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||178.78|
|SNDX Syndax Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||189.52|
|SCYX SCYNEXIS, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||192.25|
|ASMB Assembly Biosciences, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||200.56|
|TPHS Trinity Place Holdings Inc.||NYSEMKT > Consumer Services > Building operators||201.35|
|SYRS Syros Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||229.04|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||238.12|
|LJPC La Jolla Pharmaceutical Company||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||8,824.21|
|RARE Ultragenyx Pharmaceutical Inc.||NASDAQ > Health Care > Major Pharmaceuticals||10,880.38|
|RIOT Riot Blockchain, Inc||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||14,181.75|
|ADMS Adamas Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||22,090.90|
|GLYC GlycoMimetics, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||26,375.14|
|PRKR ParkerVision, Inc.||NASDAQ > Technology > Radio And Television Broadcasting And Communications Equipment||91,633.80|